Cidara Therapeutics Inc

Cidara Therapeutics — Investor Presentation (August 2019)

46 slides from Cidara Therapeutics's investor presentation, Aug 14, 2019

  1. Slide 1: New Hope for Serious Infections

    New Hope for Serious Infections Corporate Presentation August 2019 © Cidara Therapeutics 2019 | Confidential

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Because such statements are subject to risks and and whether our Cloudbreak platform can be These slides and the uncertainties, actual results may differ materially from those expanded to identify product candidates to treat or expressed or implied by such forward-looking

  3. Slide 3: Cidara's pipeline addresses multiple unmet needs

    Cidara’s pipeline addresses multiple unmet needs IND- Indication Program Discov. in vitro in vivo enable Ph 1 Ph 2 Ph 3 REZAFUNGIN Candida Intravenous Treatment Fungal Intravenous Prophylaxis CLOUDBREAK Influenza Antiviral Fc Prevention & Conjugates Treatment (AVCs) RSV, HIV, AVCs Dengue, Zika 3

  4. Slide 4: Cidara addresses multiple unmet medical needs: Rezafungin

    Cidara addresses multiple unmet medical needs Rezafungin Cloudbreak 4

  5. Slide 5: High mortality reflects fungal disease severity

    High mortality reflects fungal disease severity Overuse of azoles has driven resistant strains Crude Mortality (%) n=1,890 cases between 1995 and 20021 C. auris 60%2 >30x C. krusei 59% mortality risk if: C. glabrata 50% C. tropicalis 43% incorrect drug used C. albicans 37% treatment delayed ≥24 hrs3

  6. Slide 6: Invasive fungal infections cause high mortality post transplant

    Invasive fungal infections cause high mortality post transplant 90-day mortality % by patient category1 Bone and marrow transplantHSCT 63% Prophylaxis focus in Phase 3 trial Hematologic malignancy 52% Solid tumor 40% General medicine 38% Surgical (nontransplant) 26% HIV/AIDS 24% Solid organ transpla

  7. Slide 7: Antifungal drug development has dwindled

    Antifungal drug development has dwindled Number of New Antifungals 6 5 1 1980 1990 2000 2010 2020 amphotericin terbinafine posaconazole isavuconazole lipid forms (3) itraconazole anidulafungin fluconazole micafungin voriconazole caspofungin 7

  8. Slide 8: Rezafungin for treatment in the critically ill

    Rezafungin for treatment in the critically ill High exposure (efficacy in critically ill) REZAFUNGIN Establish novel Once-weekly dosing (ECHINOCANDIN) drug in market (early discharge and outpatients) Under-dosed No drug-drug interactions 1ST GEN Once-daily IV dosing Established safety ECHINOCANDINS

  9. Slide 9: Rezafungin for prophylaxis in hem/onc patients

    Rezafungin for prophylaxis in hem/onc patients Host and Macro-environment • Chronic immunosuppression • Novel biologics • Epidemiology - azole resistance Antifungal therapies • Drug-drug interactions • Toxicities (bone marrow, liver, kidney) • Under-dosing 9

  10. Slide 10: The Rezafungin opportunity spans ID and hematology

    The Rezafungin opportunity spans ID and hematology REZAFUNGIN Cancidas Noxafil (caspofungin) (posaconazole) ~$700M ~$700M Infectious Disease Hematology Mostly Treatment Mostly Prophylaxis Source: Cancidas – IQVIA; Noxafil – 2018 Merck Annual Report 10

  11. Slide 11: Rezafungin overall phase 3 development plan

    Rezafungin overall phase 3 development plan * Phase 3 Treatment Trial Phase 3 Prophylaxis Trial Prophylaxis against Aspergillus, Treatment of candidemia & Candida & PCP in patients Indication invasive candidiasis in patients undergoing allogeneic blood and with limited treatment options marrow trans

  12. Slide 12: STRIVE B Phase 2 data in candidemia & invasive candidiasis

    STRIVE B Phase 2 data in candidemia & invasive candidiasis Corroborates STRIVE A results and supports ReSTORE Phase 3 12

  13. Slide 13: P2 STRIVE Part B: Candidemia & Invasive Candidiasis

    P2 STRIVE Part B: Candidemia & Invasive Candidiasis Not powered for inferential statistics Overall Response Mycological & (Mycological & Mycological & Randomization 2:1 clinical clinical response): clinical response Mycological & response 1° ENDPOINT (IC only) clinical response Dose Optional dose Al

  14. Slide 14: STRIVE B: the bridge from STRIVE A to ReSTORE

    STRIVE B: the bridge from STRIVE A to ReSTORE STRIVE A (n=92) STRIVE B (n=91) RESTORE (n=184) 2017 2018 2019 2020 Rezafungin 400 / 400mg Rezafungin 400 / 200mg Caspofungin STUDY SIZE: STRIVE A + B (n=183) ≈ RESTORE (n=184) CRITERIA: Similar inclusion/exclusion, except STRIVE B enrolled patients with

  15. Slide 15: 30-Day All Cause Mortality

    30-Day All Cause Mortality Similar to the ReSTORE trial primary endpoint for FDA Death at Day 30 (%) mITT Population n/N= 1 STRIVE B Rezafungin 400/400 7/43 16.3% Rezafungin 400/2002 1/15 6.7% Caspofungin3 5/33 15.2% n/N= 1 STRIVE A + B Rezafungin 400/400 12/76 15.8% 2 Rezafungin 400/200 2/46 4.4% 3

  16. Slide 16: Investigator assessment of clinical response

    Investigator assessment of clinical response Similar to the ReSTORE trial primary endpoint for EMA Clinical Cure (%) at Day 14 mITT Population n/N= 1 STRIVE B Rezafungin 400/400 28/43 65.1% Rezafungin 400/2002 13/15 86.7% Caspofungin3 23/33 69.7% n/N= 1 STRIVE A + B Rezafungin 400/400 53/76 69.7% 2

  17. Slide 17: Overall response

    Overall response STRIVE B primary endpoint: combination of clinical and mycological responses Overall Success (%) at Day 14 mITT Population n/N= 1 STRIVE B Rezafungin 400/400 27/43 62.8% Rezafungin 400/2002 13/15 86.7% Caspofungin3 23/33 69.7% n/N= 1 STRIVE A + B Rezafungin 400/400 46/76 60.5% 2 Rez

  18. Slide 18: Topline summary of adverse events in safety population

    Topline summary of adverse events in safety population Study-Drug Related TEAEs REZAFUNGIN CASPOFUNGIN STRIVE B As expected and 400/400 mg 400/200 mg Pooled 70/50 mg observed in STRIVE A, (QWk) (QWk) Groups (QD) thethe majoritymajority ofof subjectssubjects had at least one TEAE N=46 N=18 N=64 N=34

  19. Slide 19: Our Phase 3 trial design mirrors the Phase 2 design

    Our Phase 3 trial design mirrors the Phase 2 design Phase 2 Dose Optional dose Week 1 2 3 4 5 6 7 8 9 Day 1 8 15 22 28 45 59 All cause mortality Mycological & clinical response: 1° ENDPOINT Overall response: All cause mortality: 1° ENDPOINT EMA 1° ENDPOINT FDA Phase 3 Week 1 2 3 4 5 6 7 8 9 Objectiv

  20. Slide 20: 30-Day All Cause Mortality – Post Hoc Analysis

    30-Day All Cause Mortality – Post Hoc Analysis* Rezafungin (STRIVE A + B, 400/200) vs. Caspofungin (STRIVE A + B) Rezafungin mITT: 2/46= 4.4% ACM; Caspofungin mITT: 8/61= 13.1% ACM FAVORS REZAFUNGIN FAVORS CASPOFUNGIN ReSTORE -8.8% Phase 3 trial endpoint -24.7% +0.41% requires upper limit of 95% con

  21. Slide 21: Day 14 Clinical Response – Post Hoc Analysis

    Day 14 Clinical Response – Post Hoc Analysis* Rezafungin (STRIVE A + B, 400/200) vs. Caspofungin (STRIVE A + B) Rezafungin mITT: 37/46= 80.4% Cure; Caspofungin mITT: 43/61= 70.5% Cure FAVORS REZAFUNGIN FAVORS CASPOFUNGIN ReSTORE 9.9% Phase 3 trial endpoint 26.6% -6.9% requires lower limit of 95% con

  22. Slide 22: Advantages of expanding outside of the in-hospital market

    Advantages of expanding outside of the in-hospital market Cidara ”Typical” Abx company Treatment: in- and outpatient Opportunity Prophylaxis: Inpatient treatment BMT/Hematology Outpatient IV pricing & Commercial Hospital inpatient DRG reimbursement (Part B) 13 years since last Candida ~15 Ph3 progra

  23. Slide 23: Antifungal (Cresemba) launch outpaces recent antibiotics

    Antifungal (Cresemba) launch outpaces recent antibiotics U.S. Sales Post Launch: Cresemba vs. Antibiotics 30 CRESEMBA (ANTIFUNGAL) AVYCAZ Sales ($M) 20 DALVANCE ZERBAXA ANTIBIOTICS AVERAGE 10 ORBACTIV 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Launch Quarter Cresemba (isavuconazole) is a triazole launched in 2

  24. Slide 24: Antifungals are historically big drugs globally

    Antifungals are historically big drugs globally Peak Global Company Product Class BIG PHARMA ANTIFUNGALS Sales ($) MERCK Noxafil 720M Triazole (posaconazole) Cancidas 1st Gen 680M (caspofungin) Echinocandin PFIZER Vfend 800M Triazole (voriconazole) Diflucan 1,000M Triazole (fluconazole) Eraxis 1st G

  25. Slide 25: Cidara addresses multiple unmet medical needs: Cloudbreak

    Cidara addresses multiple unmet medical needs Rezafungin Cloudbreak 25

  26. Slide 26: Vaccines for influenza have limitations

    SB 11 Vaccines for influenza have limitations Viral coverage Patient Manufacturing Strain-specific, Less effective in elderly & Challenging in a pandemic: variable coverage immune compromised long, complex production 10%-60% effective ~2-week lag time to Difficult to scale, low yields (2004-2018)1 a

  27. Slide 27: Treatments for influenza also have limitations

    SB 11 Treatments for influenza also have limitations Resistance Administration Efficacy Resistance emerges 48 hour window Limited in patients with rapidly complicated & severe disease 27

  28. Slide 28: Cloudbreak antiviral conjugates (AVCs) for influenza

    Cloudbreak antiviral conjugates (AVCs) for influenza: Potential single dose universal protection and treatment 28

  29. Slide 29: Cloudbreak platform – multimodal mechanism of action

    SB 10 Cloudbreak platform – multimodal mechanism of action: intrinsic antimicrobial activity & immune engagement Immune Pathogen Component TARGETING MOIETY Fc MOIETY Binds conserved surface target Engages innate or Direct antimicrobial activity adaptive immune system 29

  30. Slide 30: Cloudbreak AVCs combine small molecules and monoclonal antibodies

    SB 10 Cloudbreak AVCs combine the power of small molecules (SMs) and monoclonal antibodies • High potency SMs • Extended half-life Intrinsic antiviral • Broad spectrum (influenza A&B) activity • Combining multiple MOAs VIRUS Conserved, essential target 30

  31. Slide 31: What would an "ideal" product look like?

    SB 12 What would an “ideal” product look like? Broad spectrum, universal coverage Superior resistance profile Protection for High-Risk Populations Expanded efficacy window Long duration of action Rapid onset of activity Flexible administration 31

  32. Slide 32: Potential for "universal" activity in vivo

    SB 14 Potential for “universal” activity in vivo Single low doses of CB-012 protect mice in lethal infection models Coverage A/Hong Kong/68 H3N2 A/Texas/36/91 H1N1 100% CB-012 0.4 mg/kg Resistance CB-012 0.4 mg/kg Vulnerable 100% Dose Survival Efficacy 0% Neg control (Fc only) 0 Days 14 Duration Sur

  33. Slide 33: Coverage of drug resistant strains

    SB 14 Coverage of drug resistant strains Coverage Resistance CB-012 in Tamiflu-resistant H1N1 Vulnerable Dose 100% CB-012, 2mg/kg Doses 1 dose Efficacy Duration Rapid onset Survival Administration Tamiflu 20mg/kg Neg control (Fc only) 10 doses 0% 0 Days 14 1. A/Perth/261/2009, Strain H275Y 33

  34. Slide 34: Potential for protection in vulnerable patients

    SB 14 Potential for protection in vulnerable patients Lethal influenza model (H1N1: A/Puerto Rico/8/34) Coverage BALB/c mice BALB/c SCID mice Resistance Immune competent Severe Combined ImmunoDeficiency Vulnerable Efficacy 0.3 mg/kg 0.3 mg/kg Duration 100% 100% Dose CB-012 Dose CB-012 Rapid onset Ad

  35. Slide 35: Expansion of the treatment window

    SB 14 Expansion of the treatment window Coverage Treatment initiated 72 HOURS post-infection Resistance Dose CB-012: 10 mg/kg Vulnerable Tamiflu: 20 mg/kg Doses CB-012 Efficacy Duration Fc only Tamiflu Rapid onset Administration 0 24 48 72 96 HOURS INFECTION Mouse lethal endpoint model H1N1 35

  36. Slide 36: Potential for long-term single dose protection

    SB 14 Potential for long-term single dose protection Single dose given 28 days prior to viral challenge Coverage CB-012 Resistance Lethal influenza model 100% (H1N1: TX/36/91 in mice) Vulnerable Efficacy Survival Control Duration 2.5 mg/kg 0% Rapid onset -28 -14 DAYS 0 14 Administration Dose Infect

  37. Slide 37: Rapid therapeutic exposure in key tissues

    SB 14 Rapid therapeutic exposure in key tissues Coverage Resistance CB-012 lung distribution 10 mg/kg IV dose, mouse Vulnerable Efficacy Plasma Duration Concentration Cmax 1 hr CB-012: MINUTES Rapid onset Lung VACCINES: WEEKS Administration 37

  38. Slide 38: Flexible routes of administration

    SB 14 Flexible routes of administration Coverage CB-012 dosed by different routes Resistance 5 mg/kg, mouse Vulnerable Cmax 4 hr Efficacy Cmax 24 hr Duration Subq Rapid onset IM IV Administration 38

  39. Slide 39: Dose-dependent viral clearance in lungs

    Dose-dependent viral clearance in lungs Viral burden (H1N1) in mouse lung – Day 4 post-infection PFU / g (Log10) 103 104 105 106 107 108 PBS control Fc control (3 mg/kg) Oseltamivir (5 mg/kg, BID x 4) CB-012 (0.1 mg/kg) CB-012 (0.3 mg/kg) CB-012 (1.0 mg/kg) CB-012 (3.0 mg/kg) 39

  40. Slide 40: Dose-dependent reduction in inflammatory cytokines

    Dose-dependent reduction in inflammatory cytokines TNFa (Mouse lung) IL-6 (Mouse Lung) Concentration (pg/mL) Concentration (pg/mL) 0 400 800 0 1000 1500 PBS control Fc control (3 mg/kg) Oseltamivir (5 mg/kg, BID x 4) CB-012 (0.1 mg/kg) CB-012 (1.0 mg/kg) CB-012 (3.0 mg/kg) Uninfected 40

  41. Slide 41: Broad safety margin in rats and primates

    Broad safety margin in rats and primates Results of 14-day toxicity testing Therapeutic Margins 60000 NO FINDINGS FOR: Area under the curve (AUC) for maximum Clinical observations dose tested (hr*µg/mL) Hematology 40000 Clinical Chemistry Coagulation 15x 10x Urinalysis 20000 Histopathology AUC requi

  42. Slide 42: Platform expansion beyond influenza

    Platform expansion beyond influenza INFLUENZA RSV HIV DENGUE ZIKA 42

  43. Slide 43: Upcoming milestones

    Upcoming milestones 2019 2020 August Midyear Options X: new Cloudbreak data Phase 3 ReSTORE topline October IDWeek/TIMM - STRIVE A&B data 2nd half 2019 Investor Day Phase 1 subcutaneous 43

  44. Slide 44: Financial overview

    Financial overview We expect to finance our cash needs through: Summary Information ($M) June 30, 2019 • equity and debt financings, Cash $44.6 • entering into collaborations, strategic alliances and Common shares issued 26.8 licensing arrangements, • receiving government and/or Common equivalent sh

  45. Slide 45: Cidara is much more than a typical ID company

    SB 12 Cidara is much more than a typical ID company Strategic Focus Not a ‘typical’ Infectious Disease company Rezafungin Treatment Large market with low dev risk (STRIVE A + B) Rezafungin Prophylaxis Hem/onc supportive care, high unmet need Cloudbreak AVC Enormous influenza market potential & expan

  46. Slide 46: New Hope for Serious Infections

    New Hope for Serious Infections Corporate Presentation August 2019 © Cidara Therapeutics 2019 | Confidential

Cidara Therapeutics — Investor Presentation (August 2019) on 6ix